<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00602030</url>
  </required_header>
  <id_info>
    <org_study_id>SNDX-275-0401</org_study_id>
    <nct_id>NCT00602030</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Erlotinib With or Without SNDX-275 in the Treatment of Patients With Advanced NSCLC</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study With a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients With NSCLC After Failure In Up to Two Prior Chemotherapeutic Regimens for Advanced Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syndax Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syndax Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of SNDX-275 in combination
      with erlotinib in the treatment of Advanced Non-Small Cell Lung Cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progressive-free survival rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety and tolerability of SNDX-275 in combination with erlotinib</measure>
    <time_frame>from date of randomization to discontinuation due to disease progression or intolerable AE</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate pharmacokinetics of SNDX-275 in combination with erlotinib</measure>
    <time_frame>From randomization thru day 15 of Cycle 4 of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <condition>Carcinoma, Non-Small Cell Lung</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lead in Open Label Phase 1 dose-finding study to identify a safe dose of entinostat in combination with erlotinib for further evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>erlotinib (Tarceva) and entinostat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>erlotinib (Tarceva) and matched Placebo
patients in this arm who progress will be offered the opportunity to receive SNDX-275 with erlotinib for up to 6 28-day treatment cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entinostat</intervention_name>
    <description>Dose cohort 1: SNDX-275 5mg tablets on days 1 and 15 of 28-day cycle (max. 6 cycles)
Dose cohort 2: SNDX-275 10mg tablets on days 1 and 15 of 28-day cycle (max. 6 cycles)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SNDX-275</intervention_name>
    <description>entinostat 5mg or 10mg (determined by Lead in study findings) on days 1 and 15 of a 28-day cycle until progression or unacceptable toxicity develops; maximum of 6 cycles</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>erlotinib 150mg PO QD</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Cytologically or histologically confirmed NSCLC of stage IIIb or IV

          -  Received at least 1 but no more than 2 prior chemotherapy or chemoradiotherapy
             regimens for advanced NSCLC (that did not include erlotinib and valporic acid) and
             progressed based on radiologic evidence

          -  At least 1 measurable lesion by conventional or spiral CT scan

          -  ECOG performance score of 0, 1, or 2 and life expectancy of at least 6 months

          -  Paraffin-embedded tumor specimen available for correlative studies

          -  Male or female over 18 years of age

          -  Hemoglobin ≥ 9.0 g/dL; platelets ≥ 100 x 109/L; ANC ≥ 1.5 x 109/L without the use of
             hematopoietic growth factors

          -  Bilirubin and creatinine less than 2 times the upper limit of normal for the
             institution

          -  Albumin ≥ 2.5 /dL

          -  AST and ALT less than 3 times the upper limit of normal for the institution

          -  Prothrombin time less than 1.5 times the upper limit of normal for the institution

          -  Potassium, magnesium and phosphorus within the normal range for the institution
             (supplementation is permissible)

          -  Willing to use accepted and effective methods of contraception during the study (both
             men and women as appropriate) and for 3 months after the last dose of SNDX-275

          -  Patient or legally acceptable representative has granted written informed consent
             before any study-specific procedure (including special screening tests) are performed

        Exclusion Criteria

          -  Prior stem cell transplant

          -  Clinical evidence of CNS involvement

          -  Prior treatment with an HDAC inhibitor or an EGFR inhibitor

          -  Currently taking known inhibitors of CYPA4, including but not limited to atazanavir,
             clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir,
             saquinavir, telithromycin, troleandomycin, ≥ 10 mg prednisone, and voriconazole

          -  Current use of valporic acid

          -  Prior exposure to SNDX-275

          -  Systemic chemotherapy, radiotherapy, or treatment with an investigational agent
             without recovery to at least grade 1 or baseline before study drug administration

          -  Daily treatment with ≥ 10 mg prednisone within 28 days before study drug
             administration

          -  Local or whole brain palliative radiotherapy within 14 days before study drug
             administration

          -  Currently active second malignancy, or any malignancy within the last 5 years other
             than cured basal or squamous cell skin carcinoma, cervical carcinoma in situ,
             carcinoma in situ of the bladder, or papillary thyroid cancer

          -  Inability to swallow oral medications or a gastrointestinal malabsorption condition

          -  Acute infection requiring IV antibiotics, antivirals, or antifungals within 14 days
             before study drug administration

          -  Known HIV infection, or active hepatitis B or C infection

          -  Another serious or uncontrolled medical condition within 90 days before study drug
             administration such as acute myocardial infarction, angina, ventricular arrhythmias,
             hypertension, diabetes mellitus, or renal or hepatic insufficiency

          -  Known hypersensitivity to benzamides

          -  Women who are currently pregnant or breast-feeding

          -  Patient currently is enrolled in (or completed within 28 days before study drug
             administration) another investigational drug study

          -  Patient has any kind of medical, psychiatric, or behavioral disorder that places the
             patient at increased risk for study participation or compromises the ability of the
             patient to give written informed consent and/or to comply with study procedures and
             requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir Witta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rocky Mountain Cancer Centers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kartik Konduri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Oncology - Sammons Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Raju, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dayton Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HOPE (Hematology Oncology Physicians &amp; Extenders)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Specialties</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Oncology Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Florida</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Indiana Cancer Centers</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Hematology Oncology</name>
      <address>
        <city>Westminster</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph Oncology</name>
      <address>
        <city>St. Joseph</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer Care &amp; Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahonig Valley Hematology Oncology Associates</name>
      <address>
        <city>Boardman</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Oncology &amp; Hematology</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncololgy Associates of Oregon</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfax Northern Virginia Hematology-Oncology</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virgina Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highline Medical Oncology</name>
      <address>
        <city>Burien</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital/North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2008</study_first_submitted>
  <study_first_submitted_qc>January 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>April 18, 2012</last_update_submitted>
  <last_update_submitted_qc>April 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>lung neoplasms</keyword>
  <keyword>respiratory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entinostat</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

